Clinical Trial

Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity

Study acronym: DILICORT
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial´s aim is to assess if oral prednisone (compared to placebo), administered over five weeks is beneficial in terms of decreased total bilirubin (TBL): reduction of the peak of TBL at least 50% at 14 days or reduction in the time to normalisation of TBL value.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-01; most recent amendment 2024-04-04.
Trial Details
NCT Number NCT06251232
Lead Sponsor Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Conditions Hepatotoxicity, Idiosyncratic Drug Effect, Prednisone
Enrollment 60 participants
Start Date 2024-05-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-05